TECH Cash & equivalents
Cash & equivalents at Bio-Techne rose to $162M in fiscal 2025, from $152M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 842023 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$162M
FY2024 $152M
HIGH$199M FY2021
LOW$152M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $162M | +$10M |
| FY2024 | $152M | $-29M |
| FY2023 | $181M | +$8M |
| FY2022 | $173M | $-26M |
| FY2021 | $199M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · TECH company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.